Skip to content
Buy This GLP
← Research
Evidence

Is Semaglutide Cost-Effective for MASH? Three US Models

Three US models put semaglutide for MASH at $19,911, $42,200 and $80,076 per quality-adjusted life year. The lowest came from the manufacturer, and all three sit under the thresholds they used.

Editorial profile: Carla MedinaBuy This GLP Editorial Team7 min read
Semaglutide for MASH, cost per QALY gained$100k thresholdmanufacturer modelNjei, 5 yearsAbdeen, lifetime

Three US studies estimated that semaglutide was cost-effective versus standard care for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and stage F2 or F3 fibrosis. Their estimates were $19,911, $42,200 and $80,076 per quality-adjusted life year (QALY) gained in the scenarios shown here [1] [2] [3]. Each fell below the study’s chosen threshold.

Wegovy injection has FDA accelerated approval for this indication [5]. The liver trials provide the clinical context for those projections, while economic studies of weight-loss treatment address a different population. One QALY represents one year of life in full health.

Three models, three figures

The lowest ratio comes from a lifetime model taken from the perspective of a US third-party payer. The model projected 1.66 additional QALYs with semaglutide at an incremental cost of $33,031, for a ratio of $19,911 per QALY, and it was cost effective in 99.5% of simulations at a $150,000 threshold [1]. Two of its three authors are employees and shareholders of Novo Nordisk, which makes semaglutide, and the third works for a firm Novo Nordisk contracted to develop the model and write the manuscript.

An academic model from a Yale-based group ran shorter horizons for patients with F2 to F3 fibrosis and found semaglutide cost-effective at $42,200 per QALY over five years and $44,138 over ten [2]. When the model added semaglutide’s cardiovascular mortality benefit, the ratio improved to $38,324, and the authors declared no competing interests.

A third model, from Georgia Tech and Cleveland Clinic, used a lifetime horizon and a $100,000 threshold [3]. Semaglutide came in at $80,076 per QALY with an 89.8% probability of being cost-effective under the modeled assumptions. Tirzepatide came in at $42,705 per QALY. Its effect estimate came from an indirect comparison that used phase 2 data. Drug price had the largest influence in this model’s sensitivity analyses.

What the cash price does to the answer

McGovern and colleagues modeled a $499-per-month cash price for semaglutide 2.4 mg. At that assumed price, the model projected lower total costs and more QALYs than standard care [1]. The study used $499 as a scenario input. Current GLP-1 cash prices depend on the specific product, dose and payment terms.

Semaglutide against resmetirom

McGovern’s model put resmetirom at $346,810 per QALY for 80 mg and $198,607 for 100 mg [1], and the Cleveland Clinic model at $273,445, above its threshold [3]. The Yale model put it at $95,981 over five years, below a $150,000 threshold [2].

Value and effect are different rankings. The same Yale model projected that treating 100,000 patients over ten years would prevent 1,040 liver-related deaths with semaglutide and 1,180 with resmetirom [2]. Semaglutide ranked better on cost per QALY while resmetirom prevented more liver-related deaths in that projection.

Outside the US

A twelve-country economic model studied adults with type 2 diabetes. It estimated that screening followed by intensive lifestyle intervention plus semaglutide was cost-effective in eleven countries, with Tanzania the exception. The corresponding pathway with resmetirom met the threshold in eight [4]. Studies of liver screening in people with diabetes address the separate question of whom to test.

These estimates compare projected costs and health outcomes for populations. The result depends on the price, time horizon and assumptions each model uses.

Frequently asked

Is semaglutide cost-effective for MASH?
In the three US studies summarized here, semaglutide was cost-effective under each study’s assumptions. Their estimates were $19,911, $42,200 and $80,076 per quality-adjusted life year for MASH with moderate to advanced fibrosis, all below the $100,000 to $150,000 thresholds they used.
Is semaglutide more cost-effective than resmetirom?
All three models ranked semaglutide ahead on cost per QALY. They disagreed about resmetirom itself: two put it above their threshold and one, over five years, put it below $150,000. That same model projected resmetirom would prevent more liver-related deaths per 100,000 patients.
Who built the $19,911 model?
Two of its three authors are employees and shareholders of Novo Nordisk, and the third works for a firm Novo Nordisk contracted to develop the model and write the manuscript. The two academic models came in at $42,200 and $80,076.
What did the $499 cash-price scenario find?
Using $499 per month as a model input, the manufacturer-funded study projected lower costs and more health gains than standard care.
What is a QALY?
A quality-adjusted life year is one year of life in full health. Researchers use added cost per QALY gained to compare projected changes in costs and health outcomes. These studies used thresholds of $100,000 or $150,000 per QALY.

Sources

  1. [1] McGovern AJ, Cinfio F, Luo R (2026). A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States PharmacoEconomics. PMID 42503575
  2. [2] Njei B, Al-Ajlouni YA, Tanih DN, Kanmounye US, Boateng S, Halwani KW, et al. (2026). Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis Cost Effectiveness and Resource Allocation. PMID 41862906
  3. [3] Abdeen AA, Ayer T, Biswas A, Wehrle CJ, Laique SN, Aminian A (2026). Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States Diabetes, Obesity and Metabolism. PMID 42348222
  4. [4] Lazarus JV, Agirre-Garrido L, Díaz LA, Danpanichkul P, Kivuyo SL, Kondili LA, et al. (2025). Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes JAMA Network Open. PMID 41196592
  5. [5] U.S. Food and Drug Administration (2025). FDA Approves Treatment for Serious Liver Disease Known as MASH FDA. Source

Where to get it

The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

See the board →

More in Evidence